[ Price : $8.95]
In its latest batch of Warning Letters FDA cites Heritage Pharmaceuticals and Life Support Development.[ Price : $8.95]
Gilead says its Phase 3 study of Zydelig combined with bendamustine and rituximab for treating patients with relapsed chronic lymp...[ Price : $8.95]
FDA says it is requiring manufacturers of iodinated contrast media to study the potential for infants to develop underactive thyro...[ Price : $8.95]
FDA continues its crackdown against laboratory-developed test makers, sending a letter to HarmonyX about its tests for antiplatele...[ Price : $8.95]
Federal Register Notice: FDA corrects certain reference numbers in the preamble to a 9/24 final rule on environmental assessments ...[ Price : $8.95]
An opinion piece by a former FDA official in the Charleston Gazette-Mail says the U.S. would be better served if it moved more tow...[ Price : $8.95]
CDER says it is receiving reports from healthcare professionals about ongoing difficulties with the Clozapine REMS Program, includ...[ Price : $8.95]
FDA posts a guidance on Organ-Specific Warnings: Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Cou...